Clinical Trial Units
At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
- Oxford Clinical Trials Research Unit which integrates the following trials groups:
- Oxford Trauma and Emergency Care
- Oncology Clinical Trials Office
- Surgical Intervention Trials Unit
- Experimental Medicine and Rheumatology
- Centre for Rehabilitation Research in Oxford
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Centre.
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
1 February 2023
The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.
3 January 2023
Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community.
18 November 2022
A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.